Jane Street Group LLC Reduces Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Jane Street Group LLC trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 30.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,934 shares of the company's stock after selling 24,603 shares during the period. Jane Street Group LLC owned 0.06% of IDEAYA Biosciences worth $1,412,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after purchasing an additional 327,498 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of IDEAYA Biosciences by 5.9% in the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after buying an additional 282,936 shares during the last quarter. Geode Capital Management LLC raised its position in shares of IDEAYA Biosciences by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after buying an additional 43,226 shares in the last quarter. Pictet Asset Management Holding SA lifted its holdings in shares of IDEAYA Biosciences by 2.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company's stock worth $49,891,000 after acquiring an additional 46,931 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in IDEAYA Biosciences by 22.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company's stock worth $30,842,000 after acquiring an additional 220,000 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Trading Up 1.5%

IDYA opened at $18.08 on Tuesday. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $44.42. The business's 50-day moving average price is $17.63 and its 200-day moving average price is $22.11. The company has a market cap of $1.58 billion, a P/E ratio of -5.48 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period last year, the firm earned ($0.53) earnings per share. Equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Stephens restated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $54.27.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.